The global cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.8% during the forecast period. Significant research on monoclonal antibodies have been witnessed, which is providing a scope for the market growth. The availability of funding and the increasing focus of researchers and biopharmaceutical firms towards the development of monoclonal antibodies are some major factors driving the research on monoclonal antibodies. For instance, as per the Well-come Trust, over 570 monoclonal antibodies are currently in clinical testing. In 2019, 7 of the 10 best-selling novel drugs were monoclonal antibodies for the treatment of cancer and inflammatory diseases.
To Request a Sample of our Report on Cancer Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/cancer-monoclonal-antibodies-market
Additionally, the companies are collaborating for the development of novel monoclonal antibodies therapeutics for cancer. For instance, in April 2018, Boehringer Ingelheim and OSE Immunotherapeutics declared a partnership agreement for joint development of OSE-172. It is a monoclonal antibody targeting SIRP-alpha which is expressed in myeloid lineage cells. This antibody has the potential to increase anti-tumor immunity by increasing T cell activity through increasing the functionality of DC antigen presentation. The collaboration of OSE Therapeutics with Boehringer Ingelheim is its advanced approach for the treatment of cancer and will develop a new alliance to leverage the phase 1 development of OSE-172.
Scope of the Global Cancer Monoclonal Antibodies Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World
- Competitive Landscape- Amgen Inc., Eli Lilly & Co., F. Hoffman-La Roche AG, Merck & Co., Inc., and Novartis AG
Recent Strategic Initiatives in the Global Cancer Monoclonal Antibodies Market
- In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer.
- In June 2018, Pfizer Inc. announced the approval of ZIRABEV (bevacizumab-bvzr) in the US. It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer.
(Get 15% Discount on Buying this Report)
A full Report of Cancer Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- How COVID-19 impacted the market?
Ø Recovery Timeline
Ø Deviation from the pre-COVID forecast
Ø Most affected region/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Cancer Monoclonal Antibodies Market-Segmentation
By Type
- Naked
- Conjugated
- Others (Bispecific)
By Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
